Anti-HIV Medications for People Recently Infected With HIV

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

113 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is not known if anti-HIV treatment for recently infected patients improves long-term patient prognosis. The purpose of this study is to determine if a one year course of anti-HIV medications slows progression of HIV disease in adults recently infected with HIV.

Study hypothesis: A one-year course of HAART administered during acute or early seroconversion may slow the progression of HIV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intermittent Versus Continuous Medication in the Treatment of HIV

NCT00001967

HIV Infection

COMPLETED PHASE4

Intermittent vs. Continuous HAART to Treat Chronic HIV Infection

NCT00025909

HIV Infection

COMPLETED PHASE3

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

NCT00000891

HIV Infections

COMPLETED PHASE2

Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems

NCT00001097

HIV Infections

COMPLETED

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

NCT00705926

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in slower progression of HIV disease. This study will compare the virologic outcomes of recently infected adults who receive highly active antiretroviral therapy (HAART) with those who receive no treatment. This study will also compare the effects of treatment on patients who enroll within 3 months of seroconversion (acute seroconverters) with patients who enroll within 3 to 12 months of seroconversion (early seroconverters).

This study will last at least 3 years. Participants will be randomly assigned to one of two groups. Group 1 will receive HAART for 1 year; Group 2 will receive no treatment. There will be at least 20 study visits over the 3-year study period. Blood collection will occur at all study visits. A physical exam, medical and medication history, and risk behavior assessment will occur at most visits; participants will also be asked to complete an adherence questionnaire at most visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immediate Treatment Arm

Participants will receive immediate HAART for 1 year; then HAART will stopped until clinically indicated.

Group Type EXPERIMENTAL

Highly active antiretroviral therapy (HAART)

Intervention Type DRUG

Regimens will be assigned by investigators

Deferred Treatment Arm

Participants will receive no immediate HAART, but will receive HAART when HAART is clinically indicated.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Highly active antiretroviral therapy (HAART)

Regimens will be assigned by investigators

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented acute or recent HIV infection (infected in the past 12 months) as defined in the study protocol
* Antiretroviral naive. Participants who have taken antiretrovirals for postexposure prophylaxis are eligible for this study.
* Able to swallow tablets or capsules
* Willing to use acceptable forms of contraception

Exclusion Criteria

* Physician unable to design a potentially effective HAART regimen based on results of genotypic resistance testing
* Two CD4 counts of less than 350 cells/mm3 obtained at least 7 days apart within 30 days of study entry
* Viral load less than 5,000 copies/ml within 30 days of study entry in participants who have been infected with HIV-1 for more than six months prior to study entry
* Use of systemic cancer chemotherapy, systemic investigational agents, specific antiretroviral medications, or immunomodulators (growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons) within 30 days prior to study entry
* Current alcohol or drug use that, in the opinion of the investigator, would interfere with the study
* Serious illness requiring systemic treatment or hospitalization until participant either completes therapy or is clinically stable on therapy for at least 7 days prior to study entry
* Currently involuntarily incarcerated for treatment of either a psychiatric or physical (e.g., infectious disease) illness
* Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No